Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Turning Employees into Compliance Assets: Managing and Preventing Claims Based on Failed OBRA '90 and USP <800> Compliance.

International journal of pharmaceutical compounding·2026

Same author

Between Necessity and Compliance: Understanding FDA's GFI #256 for Animal Drug Compounding.

International journal of pharmaceutical compounding·2026

Same author

One Decade In and Counting: How 503B Outsourcing Facilities Are Finding Their Place in the Industry.

International journal of pharmaceutical compounding·2025

Same author

Advertising and Marketing for Compounding Pharmacies: Many Shades of Grey.

International journal of pharmaceutical compounding·2025

Same author

Navigating the Direct Importation of Active Pharmaceutical Ingredients: Compliance Considerations for Compounding Pharmacies.

International journal of pharmaceutical compounding·2025

Same author

A Collision Avoidance Algorithm for Human Motion Prediction Based on Perceived Risk of Collision: Part 2-Application.

IISE transactions on occupational ergonomics and human factors·2021

Search research articles

Related Experiment Video

Updated: Jan 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Legal Challenges to Compounding Drugs for Weight Loss.

Blinn E Combs¹, Brad Howard²

¹Brown & Fortunato, P.C., Amarillo and Dallas, Texas.

International Journal of Pharmaceutical Compounding

|September 17, 2025

Summary

Compounding pharmacies and physicians are aggressively producing and selling semaglutide and tirzepatide due to high demand and shortages. This trend carries significant legal risks despite potential financial incentives.

More Related Videos

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Related Experiment Videos

Last Updated: Jan 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Area of Science:

Pharmaceutical Compounding
Regulatory Affairs
Healthcare Economics

Background:

High demand and shortages of semaglutide and tirzepatide have created financial incentives for compounding pharmacies and outsourcing facilities.
Physicians in the weight loss sector are increasingly involved in the production and sale of these drugs, particularly for off-label weight loss use.
Lack of insurance coverage for weight loss indications reduces risks associated with federal anti-kickback and self-referral laws.

Purpose of the Study:

To examine the legal risks associated with the compounding and sale of semaglutide and tirzepatide.
To provide an overview of the regulatory framework surrounding these drugs in the compounding space.
To highlight the novel trends and associated risks in pharmaceutical compounding.

Main Methods:

Review of historical context for semaglutide production and sale.
Analysis of the current regulatory landscape for compounded drugs.
Overview of legal risks for compounders and clinical practices.

Main Results:

Compounding pharmacies and outsourcing facilities face strong financial incentives to produce semaglutide and tirzepatide.
Physicians are drawn to the lucrative market of weight loss drugs not typically covered by insurance.
Significant legal risks exist for entities avoiding branded products to compound and sell analogous drugs.

Conclusions:

The trend of compounding and selling semaglutide and tirzepatide presents substantial legal risks.
Navigating the evolving regulatory framework requires careful consideration and legal counsel.
Practitioners should seek jurisdiction-specific advice before engaging in the compounding of these drugs.